Network Italiano Per la Bioterapia Dei Tumori

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

Jedd D. Wolchok, Jeffrey S. Weber, Michele Maio et al. · Annals of Oncology · 2013 · 172 citations · Full text

Oncology, Melanoma, Clinical Trials +7

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

Anna Maria Di Giacomo, Paolo A. Ascierto, Paola Queirolo et al. · Annals of Oncology · 2014 · 139 citations · Full text

Oncology, Italian Network, Medicine +9

Challenges in lung cancer therapy during the COVID-19 pandemic

Luana Calabrò, Solange Peters, Jean‐Charles Soria et al. · The Lancet Respiratory Medicine · 2020 · 110 citations · Full text

Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy

Michele Maio, Alessia Covre, Elisabetta Fratta et al. · Clinical Cancer Research · 2015 · 101 citations · Full text

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients

Cristina Maccalli, Diana Giannarelli, Carla Chiarucci et al. · OncoImmunology · 2017 · 58 citations · Full text